BRD2 and neoplasm: For instance, the KEYNOTE-173 study assessed pembrolizumab combined with chemotherapy as a NAT for TNBC and displayed that pCR is positively correlated with tumor PD-L1 expression and sTIL levels [43], which may be a breakthrough for research on novel NAT.